

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF THE SENATE
00 AUG 11 PM 4:17

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Novartis			
2. Address <input type="checkbox"/> Check if different than previously reported 701 Pennsylvania Ave. NW Washington DC 20004 Suite 725 DC 20004			
3. Principal Place of Business (if different from line 2) City State/Zip (or Country)			
4. Contact Name Rachel King	Telephone 202-638-7429	E-mail (optional)	5. Senate ID # 9204-12
7. Client Name <input type="checkbox"/> Self Novartis Corporation	6. House ID # 33589000		

TYPE OF REPORT 8. Year 2000 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____ 11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
<p>12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> >> \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$1,460,000.00</u> Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature  Date 8/11/00

Printed Name and Title Rachel King - Vice President Page 1 of 20

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code AGR (one per page)

16. Specific Lobbying issues
S.1464,
H.R.1592,,

17. House(s) of Congress and Federal agencies contacted Check if None
Department of Agriculture
Environmental Protection Agency
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Muldoon, Joe</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Signature _____ Date 8/11/00

Printed Name and Title Rachel King - Vice President Page 2 of 20

Registrant Name: Novartis

Client Name: Novartis Corporation

Item	Description	Data
16	Lobbying Issues	Federal Insecticide, Fungicide & Rodenticide Act 59 Fed. Reg. 60412 (11/24/96) Atrazine, Simazine and Cyanazine: Notice of Initiation of Special Review Food Quality Protection Act Insect Resistance Management Genetically Engineered Crops Agriculture Appropriations Bill Regulatory Reform

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code ANI (one per page)

16. Specific Lobbying issues

17. House(s) of Congress and Federal agencies contacted Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 8/11/09

Printed Name and Title Rachel King - Vice President Page 4 of 20

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying issues
Appropriations: **FDA**
Administration Circular **A**

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Elkin, James</u>		No
<u>Bumbaugh, Deborah</u>		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Signature _____ Date 8/11/00

Printed Name and Title Rachel King - Vice President Page 5 of 20

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

- 15. General issue area code CAW (one per page)
- 16. Specific Lobbying issues

17. House(s) of Congress and Federal agencies contacted Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (If applicable)	New

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 8/11/00

Printed Name and Title Rachel King - Vice President Page 6 of 20

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CHM (one per page)

16. Specific Lobbying issues
Food Quality Protection Act

17. House(s) of Congress and Federal agencies contacted Check if None
Department of Agriculture
Environmental Protection Agency
Food & Drug Administration
House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Muldoon, Joe</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Signature _____ Date 8/11/00

Printed Name and Title Rachel King - Vice President Page 7 of 20

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific Lobbying issues
S.1172/ H.R. 1598, Patent Fairness Act of 1999,
H.R.2654, American Inventors Protection Act of 1999,
H.R.2100, Antitampering Act of 1999,
H.R.1907, American Inventors Protection Act of 1999,

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Elkin, James		No
Drake, David		No
Casserty, Dan		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit

Signature _____ Date 8/11/00

Printed Name and Title Rachel King - Vice President Page 8 of 20

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code ENV (one per page)

16. Specific Lobbying issues
S.1090/H.R. 1300, Superfund Program Completion Act of 1999,
H.R.1657, Children's Environmental Protection and Right to Know Act of 1999.

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Drake, David		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit

Signature _____ Date 8/11/00

Printed Name and Title Rachel King - Vice President Page 9 of 20

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code FOO (one per page)

16. Specific Lobbying issues
S.251, S.860, H.R. 830, H.R. 1145, Country of Origin Labeling,
S.1155/H.R. 2129, National Uniformity for Food Act of 1999,
H.R.3377, Genetically Engineered Food Right to Know Act,
H.R.1592, Regulatory Fairness and Openness Act of 1999,
59 Fed. Reg. 66412 (11/24/96) Atrazine, Simazine and Cyanazine: Notice of Initiation of Special Review
Food Quality Protection Act
GMO Labeling
Juice HACCP Proposal Regulations
USDA Expanded Enforcement

17. House(s) of Congress and Federal agencies contacted Check if None
Department of Agriculture
Environmental Protection Agency
Food & Drug Administration
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Drake, David		No
Muldoon, Joe		No
Hailer, Sarah		No
King, Rachel		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Signature _____ Date 8/11/00

Printed Name and Title Rachel King - Vice President Page 10 of 20

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code GOV (one per page)

16. Specific Lobbying issues
H.R.1778, Federal Election Law Integrity Act of 1999,
S.746, Regulatory Improvement Act of 1999,

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Drake, David</u>		<u>No</u>
<u>King, Rachel</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 8/11/00

Printed Name and Title Rachel King - Vice President Page 11 of 20

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

- 15. General issue area code HCR (one per page)
- 16. Specific Lobbying issues
H.R. 4607, Medicare Prescription Drug Act of 2006,
S.2807, Medicare Prescription Drug and Modernization Act of 2006,

- 17. House(s) of Congress and Federal agencies contacted Check if None
Drug Enforcement Administration
Food & Drug Administration
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Elkin, James</u>		<u>No</u>
<u>Bumbaugh, Deborah</u>		<u>No</u>
<u>King, Rachel</u>		<u>No</u>
<u>Casserly, Dan</u>		<u>No</u>

- 19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Signature _____ Date 8/11/00

Printed Name and Title Rachel King - Vice President Page 12 of 20

Registrant Name: Novartis

Client Name: Novartis Corporation

Item	Description	Data
16	Lobbying Issues	<p>Snowe/Wyden The Senior Prescription Insurance Coverage Equity Act Breaux/Thomas Medicare Reform Plan Health Insurance Portability and Accessibility Act FDA Modernization Act Pediatric Studies Program Medical Records Privacy - Senators Jeffords, Bennett, Leahy, Kennedy Bills Chairman's Mark (HELP Confidentiality Bills) Xenotransplantation Prospective Payment System Balanced Budget Refinement Act</p>

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code LBR (one per page)

16. Specific Lobbying issues
OSHA Ergonomics Legislation

17. House(s) of Congress and Federal agencies contacted Check if None
Department of Labor
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Drake, David</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 8/11/00

Printed Name and Title Rachel King - Vice President Page 14 of 20

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues
H.R.3887/S. 2232, Medicare Wellness Act of 2000,
S.841 (Kennedy), ,
H.R.664/S. 731, Prescription Drug Fairness for Seniors Act of 1999,
H.R.2030, Medicare Patient Access to Technology Act of 1999,
H.R.1885/S. 1191, International Prescription Drug Parity Act,
H.R.1796, Medicare Chronic Disease Prescription Drug Benefit Act of 1999,
H.R.1115/S. 631, Immunosuppressive Drug Coverage Extension Act of 1999,
H.R.1090, Medicare Full Access to Cancer Treatment Act of 1999,
Snowe/Wyden Seniors Prescription Insurance Coverage Equity Act

17. House(s) of Congress and Federal agencies contacted Check if None
Department of Health & Human Services
Food & Drug Administration
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Elkin, James		No
Drake, David		No
Bumbaugh, Deborah		No
King, Rachel		No
Casserly, Dan		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Signature _____ Date 8/11/08

Printed Name and Title Rachel King - Vice President Page 15 of 20

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

- 15. General issue area code NAT (one per page)
- 16. Specific Lobbying issues

17. House(s) of Congress and Federal agencies contacted Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 8/11/00

Printed Name and Title Rachel King - Vice President Page 16 of 20

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific Lobbying issues

17. House(s) of Congress and Federal agencies contacted Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 8/11/00

Printed Name and Title Rachel King - Vice President Page 17 of 20

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific Lobbying issues
R&D Tax Credit

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Drake, David</u>		<u>No</u>
<u>King, Rachel</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Signature _____ Date 8/11/00

Printed Name and Title Rachel King - Vice President Page 18 of 20

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific Lobbying issues
Economic Sanctions
SRM Ban/BSE
China/World Trade Organization
Fast Track Negotiating Authority

17. House(s) of Congress and Federal agencies contacted Check if None
Department of Commerce
Food & Drug Administration
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Haller, Sarah		No
King, Rachel		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG To the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Signature _____ Date 8/11/00

Printed Name and Title Rachel King - Vice President Page 19 of 20

Registrant Name: Novartis

Client Name: Novartis Corporation

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code WAS (one per page)

16. Specific Lobbying issues

17. House(s) of Congress and Federal agencies contacted Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 8/11/00

Printed Name and Title Rachel King - Vice President Page 20 of 20